Cartesian Therapeutics eliminates chief scientific officer position

Cartesian Therapeutics Inc. (NASDAQ: RNAC) eliminated the chief scientific officer position and terminated Christopher Jewell without cause, effective November 14, 2025, according to a company statement.

The company delivered the termination notice to Jewell on October 15, 2025. Jewell entered into a separation agreement with Cartesian Therapeutics on October 20, 2025.

The information was disclosed in a company filing based on the separation agreement between the parties.

You May Also Be Interested In

• Exchange Bank declares Q3 dividend, CEO to retire in 2027
• Commercial National Financial Corporation (CEFC) Declares $0.15 Quarterly Dividend; 3.8% Yield
• HCW Biologics (HCWB) files for 1.24M share offering by selling stockholders